Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 14/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | CTSA | P10619 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2062370 | 0.86 | KCNA5 (0.61) | KCNA5KCNH2CTSA | |
| SCHEMBL2063808 | 0.85 | KCNA5 (0.61) | KCNA5KCNH2 | |
| SCHEMBL2063464 | 0.85 | KCNA5 (0.62) | KCNA5KCNH2PDE4DPDE4ACTSA | |
| SCHEMBL2063865 | 0.84 | KCNA5 (0.61) | KCNA5KCNH2PDE4DCTSA | |
| SCHEMBL884817 | 0.82 | PDE4A (0.46) | KCNA5KCNH2PDE4DPDE4A | |
| SCHEMBL2062680 | 0.82 | KCNA5 (0.60) | KCNA5KCNH2 | |
| SCHEMBL884335 | 0.81 | KCNA5 (0.53) | KCNA5KCNH2PDE4D | |
| SCHEMBL2062960 | 0.81 | KCNA5 (0.60) | KCNA5KCNH2CTSA | |
| SCHEMBL2064429 | 0.81 | KCNA5 (0.69) | KCNA5KCNH2 | |
| SCHEMBL884604 | 0.81 | KCNA5 (0.60) | KCNA5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233897-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | claimed |
| US-8148535-B2 | Potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090233897-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233897-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | KCNA5 11/4885KCNH2 3/4885PDE4D 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.